Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Jacobio Pharmaceuticals Group Co's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 206.38.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Jacobio Pharmaceuticals Group Co's liquidation value for the
six
months ended in Dec. 2025 was $81.87 Mil.
Jacobio Pharmaceuticals Group Co (OTCPK:JBPHF) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Jacobio Pharmaceuticals Group Co's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:
2. In Ben Graham's calculation of liquidation value, Jacobio Pharmaceuticals Group Co's accounts receivable are only considered to be worth 75% of book value:
Jacobio Pharmaceuticals Group Co's liquidation value for the quarter that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co Change In Receivables Related Terms
Jacobio Pharmaceuticals Group Co Change In Receivables Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co Change In Receivables Chart
Jacobio Pharmaceuticals Group Co Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of $0.00 Mil mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a Change In Receivables of $0.00 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Jacobio Pharmaceuticals Group Co and its competitors.
Is Jacobio Pharmaceuticals Group Co's Change In Receivables too high?
Jacobio Pharmaceuticals Group Co's current Change In Receivables is $0.00 Mil. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Change In Receivables compare to VRTX and REGN?
Jacobio Pharmaceuticals Group Co's Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Jacobio Pharmaceuticals Group Co and its competitors. Jacobio Pharmaceuticals Group Co's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co (JBPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.30, compared to a current price of $0.64 — trading 113.4% above its estimated fair value. The current Change In Receivables is $0.00 Mil. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 32/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Change In Receivables is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of $0.64 is trading 113.4% above its estimated GF Value™ of $0.30.
GuruFocus considers Jacobio Pharmaceuticals Group Co to be Significantly Overvalued.
Key valuation signals for JBPHF:
Change In Receivables: $0.00 Mil
GF Value™: $0.30 vs. price of $0.64 (113.4% above fair value)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Business Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
32GF Score
Get the complete analysis for JBPHF
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
